AlphaGalileo > Item Display alphagalileo.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alphagalileo.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, May 19, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been presented as an abstract online publication at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract #e14547, 5:00 PM, U.S. East Time, Wednesday, May 19, 2021).
The study, presented at the 2021 ASCO annual meeting by abstract, was led by Professor Lin Shen from Beijing Cancer Hospital, and was a Phase I study of MSB2311 with a unique pH-dependent antigen binding property in Chinese patients with advanced solid tumors and lymphoma. Its primary objectives were to e
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, May 13, 2021 /PRNewswire/ Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies will be presented as an abstract online publication at the 57th American Society of Clinical Oncology (ASCO) Annual Meeting. The 2021 ASCO Annual Meeting will be held online from June 4th to June 8th EDT.
Online Publication
Title: Updated safety and efficacy of MSB2311 (an Anti-Programmed Death-Ligand 1 Antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase I study.
Micorscope is used by researcher who use her hands holding and adjusting while science research in laboratory
A new research led by Cornell University says it finds “little to no evidence” of a link between a person’s normal blood levels of vitamin D and risk of getting COVID-19.
In the most comprehensive study of its kind to date, the research did not also find the severity of an infection.
Multiple studies had suggested an association between vitamin D and COVID-19 risk, raising hopes that vitamin D supplements might help to prevent or minimise infections – speculation that has received widespread media attention and boosted consumer interest.